Conceptual Framework: Symptom-Producing versus Capacity-Limiting Mechanisms

Chapters 6–13 of this document establish that ME/CFS involves profound capacity-limiting pathophysiology: mitochondrial ATP synthesis deficiency, reduced cardiac output and cerebral blood flow, hypoxic metabolic drift, and neurovascular uncoupling. These mechanisms restrict the total work capacity and energy output available to a patient. A patient with severe mitochondrial dysfunction may theoretically have preserved neurochemical signaling: the brain is not activated with cytokines, neurotransmitter systems are not dysregulated, pain pathways are not sensitized. Yet such a patient would still be disabled by energy lack.

Symptom-producing mechanisms—the focus of this chapter—operate on a different axis. A patient with robust ATP synthesis, preserved cardiac output, and normal metabolic flexibility could nonetheless feel profoundly exhausted, cognitively impaired, and in pain if subjected to a sufficient barrage of pro-inflammatory cytokines, disrupted neurochemical signaling, and central sensitization. The distinction matters clinically: capacity-limiting mechanisms set the “ceiling” on what a patient can do; symptom-producing mechanisms determine how the patient feels across any level of capacity.

In ME/CFS, both axes are disrupted. A patient may be experiencing both ATP synthesis deficiency (Chapter 6) and cytokine-driven fatigue signals (Section 15.4); both reduced cardiac output (Chapter 7) and mast cell-mediated brain fog (Section 15.9). The presence of capacity-limiting pathology makes symptom-producing mechanisms more salient, not less: cytokine fatigue signal is more easily interpreted as danger when the body is actually energy-depleted; pain signals are amplified by central sensitization when tissues are genuinely hypoxic. The interaction produces a multiplicative burden rather than a simple sum.

This distinction also has therapeutic implications. A treatment that increases mitochondrial ATP (e.g., CoQ10) without addressing inflammatory signaling will restore capacity without resolving symptoms. Conversely, a treatment that suppresses cytokine signaling (e.g., anti-TNF monoclonal antibody) without addressing energy metabolism will improve how the patient feels without expanding what the patient can do. Optimal treatment addresses both axes.

The sections that follow trace the major symptom-producing pathways: the sickness behavior cascade that integrates multiple cytokine signals into a coordinated malaise program (Sections 15.2), followed by specific neurochemical generators of fatigue and cognitive dysfunction (Sections 15.3–15.9), then systems-level amplifiers that transduce these signals into multi-organ dysfunction (Sections 15.10–15.15), and finally synthesis models and therapeutic implications (Sections 15.16–15.19).